Table 7.

Table of disease characteristics of the patients studied. NDMM: newly diagnosed multiple myeloma; AD: active disease; SD: stable disease; PD: progressive disease; PR: partial response; VGPR: very good partial response; CR: complete remission; MRD neg.: minimal residual disease negativity; VTD: bortezomib–thalidomide–dexamethasone; RVd: lenalidomide–bortezomib–dexamethasone; VCD: bortezomib–cyclophosphamide–dexamethasone.

Characteristics of the Cohort
All patients (n = 66)
NDMM (naive after diagnosis) 8/66—12.1%			Non-NDMM (treated) 58/66—87.9%
Active or non-active disease
AD—without NDMM 17/58—29.3%			Non-AD 41/58—70.7%
Disease status in relation to the therapeutic response
SD 3/58—5.2%	PD 14/58—24.1%	PR 10/58—17.2%	VGPR 13/58—22.4%	CR 11/58—19%	MRD-neg. 7/58—12.1%
ISS
Stage I All: 8/57—14% Analyzed: 4/31		Stage II All: 24/57—42.1% Analyzed: 13/31		Stage III All: 25/57—43.9% Analyzed: 14/31
R-ISS
Stage I All: 5/44—11.4 Analyzed: 4/31		Stage II All: 24/44—54.5% Analyzed: 13/31		Stage III All: 15/44—34.1% Analyzed: 14/31
Cytogenetic risk
Standard All: 22/48—45.8% Analyzed: 14/27—51.9%			high All: 26/48—50% Analyzed: 13/27—44.4%
Treatments
Off treatment 0/58—0%			On active treatment 58/58—100%
Induction therapy
VTD 37/66—56.1%		RVd 3/66—4.5%	VCD 11/66—16.7%	Other 15/66—22.7%
Salvage or second line therapy
VTD 4/34—11.8%		RVd 8/34—23.5%	VCD 6/34—17.6%	Other 16/34—47.1%
Autologous stem cell transplantation
Transplanted 17/66—25.8% single: 17/17—100% tandem: 0/17—0%			Non-transplanted 49/66—74.2% candidate for transplant: 25/49—51%